<p>在昨天发布的一份报告中，摩根士丹利的 David Bailey 对 Resmed Inc CHESS 存托凭证维持了买入评级，比例为每普通股 10 个 CDI。该公司的股票今天收盘价为 28.78 澳元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>根据 TipRanks 的数据，Bailey 是一位 4 星分析师，平均回报率为 10.0%，成功率为 45.92%。Bailey 覆盖医疗保健行业，专注于 Ramsay Health Care、Telix Pharmaceuticals 和 Cochlear 等股票。</p>
<p>Resmed Inc CHESS 存托凭证的分析师共识为强烈买入，目标价格共识为 43.13 澳元，相较于当前水平有 49.86% 的上涨空间。在 5 月 4 日发布的一份报告中，Morgans 也对该股票维持了买入评级，目标价格为 41.72 澳元。</p>

瑞思迈

<p>摩根士丹利分析师大卫·贝利对瑞思迈（Resmed Inc）CHESS 存托凭证维持 “买入” 评级，收盘价为 28.78 澳元。分析师共识为 “强烈买入”，目标价为 43.13 澳元，意味着潜在上涨幅度为 49.86%。贝利是一位四星级分析师，之前在 5 月份的报告中设定的目标价为 41.72 澳元。他覆盖医疗保健行业，关注的公司包括拉姆齐医疗（Ramsay Health Care）和泰利克斯制药（Telix Pharmaceuticals）</p>

<p>In a report released yesterday, David Bailey from Morgan Stanley maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. The company’s shares closed today at A$28.78.</p>
<div class="lb-trans"><p>在昨天发布的一份报告中，摩根士丹利的 David Bailey 对 Resmed Inc CHESS 存托凭证维持了买入评级，比例为每普通股 10 个 CDI。该公司的股票今天收盘价为 28.78 澳元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>According to TipRanks, Bailey is a 4-star analyst with an average return of 10.0% and a 45.92% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Ramsay Health Care, Telix Pharmaceuticals, and Cochlear .</p>
<div class="lb-trans"><p>根据 TipRanks 的数据，Bailey 是一位 4 星分析师，平均回报率为 10.0%，成功率为 45.92%。Bailey 覆盖医疗保健行业，专注于 Ramsay Health Care、Telix Pharmaceuticals 和 Cochlear 等股票。</p>
</div><p>Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh has an analyst consensus of Strong Buy, with a price target consensus of A$43.13, which is a 49.86% upside from current levels. In a report released on May 4, Morgans also maintained a Buy rating on the stock with a A$41.72 price target.</p>
<div class="lb-trans"><p>Resmed Inc CHESS 存托凭证的分析师共识为强烈买入，目标价格共识为 43.13 澳元，相较于当前水平有 49.86% 的上涨空间。在 5 月 4 日发布的一份报告中，Morgans 也对该股票维持了买入评级，目标价格为 41.72 澳元。</p>
</div>

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Morgan Stanley

Tip Ranks

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

摩根士丹利

Ramsay Health Care Limited

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals

Cochlear Limited

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

瑞思迈公司 CHESS 存托权益以每 10 个 CDI 对应一股普通股的比例（RMD）获得摩根士丹利的买入评级